ArticleDiscover oncology2025
Role of microRNA-183 based theranostics through targeting TPM1 in bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-183 (miR-183-5p), a noncoding RNA, is upregulated in bladder carcinoma (BC). Although it has been implicated in oncogenesis, its precise regulatory effects and biological functions remain unclear. Tropomyosin-1 (TPM1) was shown to be downregulated in solid tumors and was previously identified as a novel tumor suppressor gene.
objectivesOur study focuses on the prognostic, diagnostic, and therapeutic potential of miR-183-5p in bladder carcinoma and assess TPM1 gene targets and their modulatory functions.
methodsUrine cytology, cystectomy and transurethral resection (TUR) biopsies from 148 BC patients were collected. TPM1 protein and miR-183-5p expressions were assessed through immunohistochemistry (IHC) and real-time PCR respectively. In vitro assay investigated the effect of miR-183-5p on TPM1mRNA in bladder carcinoma cell lines, then confirmed by comparing miR-183-5p mimics in non-cancerous and urothelial carcinoma cell lines. Concomitant TPM1 gene expression was examined, and the theranostic miR-183-5p potential was evaluated.
resultsUpregulation of miR-183-5p expression in BC tissue biopsies and urine cytologies was noted, contrasting the downregulation of TPM1 protein expression in the high-grade, high-stage, lymph node metastatic BC tissues (in comparison to non-cancerous, low-grade, low-stage non-lymph node metastasizing BCs). Moreover, the miR-183-5p oncogenic influence was responsive in targeting TPM1 gene at 3'UTR region, and miR‑183‑5p.1 restricted TPM1 expression in T24 cells.
conclusionThis study provides the first illustration of the miR-183-5p-TPM1 axis in bladder carcinoma, supporting the theranostic role of miR-183-5p as an onco-miR in BC progression, diagnosis, and prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.